GENMAB AS SP.ADR/1/10DK 1 Total Liabilities

Latest as of December 2025: €7.03 Billion EUR ≈ $8.21 Billion USD

GENMAB AS SP.ADR/1/10DK 1 total liabilities. Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has total liabilities worth €7.03 Billion EUR (≈ $8.21 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GE91 financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

Total liabilities of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's total liabilities have evolved over time, based on quarterly financial data. Explore GE91 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

GENMAB AS SP.ADR/1/10DK 1 Competitors by Total Liabilities

The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their total liabilities.

Company	Country	Total Liabilities
HAIER SM.HME UNSP.ADR/4 F:HAI0	Germany	€182.54 Billion
Valterra Platinum Limited JSE:VAL	South Africa	ZAC77.22 Billion
Emera Incorporated NYSE:EMA	USA	$24.34 Billion
Banco de Credito e Inversiones SN:BCI	Chile	CL$74.12 Trillion
Bosch Limited NSE:BOSCHLTD	India	Rs63.06 Billion
Nippon Sanso Holdings Corp. NYSE:NPXYY	USA	$1.51 Trillion
POSCO Holdings Inc NYSE:PKX	USA	$42.81 Trillion
Hithink RoyalFlush Info Network SHE:300033	China	CN¥6.34 Billion

Liability Composition Analysis (2021–2025)

This chart breaks down GENMAB AS SP.ADR/1/10DK 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENMAB AS SP.ADR/1/10DK 1 (GE91) total assets.

Liquidity & Leverage Metrics

GENMAB AS SP.ADR/1/10DK 1 Total Liabilities Ratios Explained

GENMAB AS SP.ADR/1/10DK 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	2.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.20	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.55	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how GENMAB AS SP.ADR/1/10DK 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)

The table below shows the annual total liabilities of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025.

Year	Total Liabilities	Change
2025-12-31	€7.03 Billion ≈ $8.21 Billion	+452.55%
2024-12-31	€1.27 Billion ≈ $1.49 Billion	+132.79%
2023-12-31	€546.23 Million ≈ $638.60 Million	+33.77%
2022-12-31	€408.32 Million ≈ $477.37 Million	+10.33%
2021-12-31	€370.09 Million ≈ $432.67 Million	--

About GENMAB AS SP.ADR/1/10DK 1

F:GE91 Germany Biotechnology

Market Cap

$17.14 Billion

€14.66 Billion EUR

Market Cap Rank

#1574 Global

#352 in Germany

Share Price

€23.80

Change (1 day)

+3.48%

52-Week Range

€17.00 - €29.80

All Time High

€44.40